Posted on 14/12/04
Ottawa considers changing patent rules
The federal government has proposed amending the country's drug patent regulations to eliminate the drug industry's ability to delay generic competition with pre-emptive lawsuits.Known as evergreening, the practice now allows drug manufacturers, which already have 20-year patent protection, to trigger further 24-month extensions, making it difficult for generic firms to produce cheaper copies of brand-name drugs.
The full text of this article has 258 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
